Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00599872 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies
A Phase 3 study of Allergic Rhinitis, sponsored by Greer Laboratories.
- Completed
- Registry status
- Phase 3
- Development phase
- 430
- Enrollment target
- 20
- Study locations
NCT00599872: Completed Phase 3 study of Allergic Rhinitis, sponsored by Greer Laboratories.
NCT00599872 is a Phase 3 study of Allergic Rhinitis that has completed, run by Greer Laboratories. The registered enrollment target is 430 participants, above the 87-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (394% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00599872, a Phase 3 study of Allergic Rhinitis, has completed, sponsored by Greer Laboratories.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 430 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration
Primary Outcome
Symptom score defined as sum of scores from eight symptoms rated 0-3 (0=absent, 1=mild, 2=moderate, 3=severe): ocular (itchiness, swelling/redness, and watery eyes/tears), nasal (sneezing, itching, runny and stuffy nose), and ears (itching). Average daily RSS ranged from 0-48; A lower score was more favorable. The average daily RSS was computed for each subject by: (1) summing the 8 individual allergy symptoms recorded in the morning (AM RSS) and the evening (PM RSS); (2) forming the daily RSS
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Standardized Ragweed Allergenic Extract
Study Locations (20)
Ohio
- Allergy and Respiratory Center - Canton
- Bernstein Clinical Research Center - Cincinnati
- Cleveland Clinic - Cleveland
- Toledo Center for Clinical Research - Sylvania
Nebraska
- Asthma, Immunology and Allergy Association, LLC - Lincoln
- Midwest Allergy and Asthma Clinic, PA - Omaha
- Creighton University - Omaha
Iowa
- Iowa Clinical Research Corporation - Iowa City
- University of Iowa Hospitals and Clinics - Iowa City
Kansas
- College Park Family Care Center - Overland Park
- Kansas City Allergy and Asthma - Overland Park
Missouri
- Clinical Research of the Ozarks - Rolla
- Midwest Clinical Research, LLC - St Louis
New Jersey
- Ocean Allergy and Respiratory Research Center - Brick
- Pulmonary and Allergy Associates, PA - Summit
Illinois
- Sneeze, Wheeze, & Itch Associates - Normal
Indiana
- Welborn Clinic - Evansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 430 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-12 |
| Phase | Phase 3 |
What the finished NCT00599872 record still lists
NCT00599872 is an interventional study that assigns participants to a tested intervention. The registered 430 participants enrollment target is mid-sized for trials with a published cap, above the 87-participant average among 23 other Allergic Rhinitis trials with a reported enrollment target (394% higher).
The record links to 1 condition, with Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00599872 names 20 study sites across 11 states, led by Ohio, Nebraska, Iowa.
Frequently Asked Questions
What is clinical trial NCT00599872 about?
NCT00599872 is a clinical study titled "Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies". The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration
What is the current status of trial NCT00599872?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 430 participants. The study started on 2008-03. Estimated completion is 2008-12.
What conditions does trial NCT00599872 study?
This clinical trial studies the following conditions: Allergic Rhinitis.
What interventions are being tested in trial NCT00599872?
The interventions under investigation include: Placebo (BIOLOGICAL), Standardized Ragweed Allergenic Extract (BIOLOGICAL).
Who is sponsoring clinical trial NCT00599872?
This trial is sponsored by Greer Laboratories, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00599872 being conducted?
This trial has 20 study locations across Illinois, Indiana, Iowa, Kansas, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00599872's enrollment target sits among peer trials
430 1st of 23 higher than 23 of 23 other Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
COMPLETED · Phase 3
-
3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
COMPLETED · Phase 3
-
Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?
RECRUITING · NA
-
Viral Mucosal Reprogramming
RECRUITING · Phase 2
-
Repurposed Use of Allergic Rhinitis and Allergic Asthma Drug to Reduce Vertigo and Hearing Loss in Meniere's Disease
ACTIVE NOT RECRUITING · Phase 4
-
Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05327023 · 430 participants · Phase 1
Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies
- NCT05457985 · 430 participants · NA
Testing Adaptive Interventions to Improve Posttraumatic Stress Disorder Treatment Outcomes in Federally Qualified Health Centers
- NCT05532982 · 430 participants
Parkinson's Disease in Asian Americans
- NCT05844891 · 430 participants · NA
Telehealth-Enhanced Asthma Care for Home After the Emergency Room
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia